Lorvotuzumab (CAS: 339306-30-8)
Lorvotuzumab is a humanized IgG1κ monoclonal antibody that targets CD56 (NCAM1), a protein found on tumor cells in cancers like small-cell lung cancer, ovarian cancer, and multiple myeloma.
Key Features:
- Target: Specifically binds to CD56, expressed on various tumor cells.
- Mechanism: Used to develop antibody-drug conjugates (ADCs) that deliver cytotoxic agents directly to CD56-expressing tumor cells.
- Therapeutic Use: Investigated for treating small-cell lung cancer, ovarian cancer, and multiple myeloma.
Applications:
- Cancer Research: Help to create ADCs targeting CD56-positive tumors, enhancing treatment precision while reducing systemic toxicity.
- ADC Development: Part of Lorvotuzumab mertansine, an ADC that targets CD56-expressing tumors with a cytotoxic payload.
Handling and Storage:
- Storage: Store at -20°C, away from light.
- Precautions: Use protective equipment and handle in a well-ventilated area.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
